Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 2827

1.
2.

Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: importance of patient selection and implant quality.

Kollmeier MA, Stock RG, Stone N.

Int J Radiat Oncol Biol Phys. 2003 Nov 1;57(3):645-53.

PMID:
14529768
3.

Tumor control outcomes of patients treated with trimodality therapy for locally advanced prostate cancer.

Copp H, Bissonette EA, Theodorescu D.

Urology. 2005 Jun;65(6):1146-51.

PMID:
15922433
6.

Five-year biochemical outcome following permanent interstitial brachytherapy for clinical T1-T3 prostate cancer.

Merrick GS, Butler WM, Galbreath RW, Lief JH.

Int J Radiat Oncol Biol Phys. 2001 Sep 1;51(1):41-8.

PMID:
11516849
7.

Multimodality radiotherapy and androgen ablation in the treatment of clinically localized prostate cancer: early results in high risk patients.

Coblentz TR, Bissonette EA, Williams KR, Theodorescu D.

Prostate Cancer Prostatic Dis. 2002;5(3):219-25.

8.

PSA bounce predicts early success in patients with permanent iodine-125 prostate implant.

Patel C, Elshaikh MA, Angermeier K, Ulchaker J, Klein EA, Chehade N, Wilkinson DA, Reddy CA, Ciezki JP.

Urology. 2004 Jan;63(1):110-3.

PMID:
14751360
9.

Prostate-specific antigen spikes after permanent prostate brachytherapy.

Merrick GS, Butler WM, Wallner KE, Galbreath RW, Anderson RL.

Int J Radiat Oncol Biol Phys. 2002 Oct 1;54(2):450-6.

PMID:
12243821
10.

Unification of a common biochemical failure definition for prostate cancer treated with brachytherapy or external beam radiotherapy with or without androgen deprivation.

Fitch DL, McGrath S, Martinez AA, Vicini FA, Kestin LL.

Int J Radiat Oncol Biol Phys. 2006 Dec 1;66(5):1430-9. Epub 2006 Jun 12.

PMID:
16765527
11.

Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995.

Kupelian P, Kuban D, Thames H, Levy L, Horwitz E, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A.

Int J Radiat Oncol Biol Phys. 2005 Feb 1;61(2):415-9.

PMID:
15667961
12.
13.

Relationship between percent positive biopsies and biochemical outcome after permanent interstitial brachytherapy for clinically organ-confined carcinoma of the prostate gland.

Merrick GS, Butler WM, Galbreath RW, Lief JH, Adamovich E.

Int J Radiat Oncol Biol Phys. 2002 Mar 1;52(3):664-73.

PMID:
11849788
14.

Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data.

Teh BS, Ayala G, Aguilar L, Mai WY, Timme TL, Vlachaki MT, Miles B, Kadmon D, Wheeler T, Caillouet J, Davis M, Carpenter LS, Lu HH, Chiu JK, Woo SY, Thompson T, Aguilar-Cordova E, Butler EB.

Int J Radiat Oncol Biol Phys. 2004 Apr 1;58(5):1520-9.

PMID:
15050332
15.

Influence of body mass index on biochemical outcome after permanent prostate brachytherapy.

Merrick GS, Butler WM, Wallner KE, Galbreath RW, Allen Z, Lief JH, Adamovich E.

Urology. 2005 Jan;65(1):95-100.

PMID:
15667872
16.

[Biochemical control after conformal, 3 dimensional radiotherapy of prostatic carcinoma].

Geinitz H, Zimmermann F, von Wedel E, Thamm R, Busch R, Feldmann HJ, Molls M.

Strahlenther Onkol. 2002 Jul;178(7):369-77. German.

PMID:
12163991
17.

Failure to achieve a PSA level <or=1 ng/mL after neoadjuvant LHRHa therapy predicts for lower biochemical control rate and overall survival in localized prostate cancer treated with radiotherapy.

Mitchell DM, McAleese J, Park RM, Stewart DP, Stranex S, Eakin RL, Houston RF, O'Sullivan JM.

Int J Radiat Oncol Biol Phys. 2007 Dec 1;69(5):1467-71. Epub 2007 Aug 8.

PMID:
17689886
19.

Combined modality treatment in the management of high-risk prostate cancer.

Stock RG, Cahlon O, Cesaretti JA, Kollmeier MA, Stone NN.

Int J Radiat Oncol Biol Phys. 2004 Aug 1;59(5):1352-9.

PMID:
15275720
20.

Finasteride and flutamide as potency-sparing androgen-ablative therapy for advanced adenocarcinoma of the prostate.

Brufsky A, Fontaine-Rothe P, Berlane K, Rieker P, Jiroutek M, Kaplan I, Kaufman D, Kantoff P.

Urology. 1997 Jun;49(6):913-20.

PMID:
9187700

Supplemental Content

Support Center